Novo Nordisk stock consolidates as Q1 profit beats forecasts

Traders Union
All News
Financial News
Novo Nordisk trades flat at $45.76

Highlights

Novo Nordisk surpassed Q1 2026 profit forecasts with DKK 32.86 billion, driven by strong Wegovy sales and a successful oral pill launch.
The company narrowed its full-year 2026 guidance, citing slower-than-expected declines in sales and profit amid heightened competition from Eli Lilly’s new FDA-approved obesity drug.
NVO trades in a consolidation phase near $45.76, with overbought signals and an expected weekly range of $44.90–$47.10, suggesting limited upside and potential for a pullback.

Profit beat and tighter outlook as Wegovy demand offsets new competition

Novo Nordisk posted first-quarter 2026 results with adjusted operating profit of 32.86 billion Danish crowns, topping forecasts as continued strong demand for its weight-loss drug Wegovy and the successful launch of its oral pill supported performance. The company simultaneously tightened its full-year 2026 outlook, now guiding for smaller declines in sales and profit than previously expected, which reflects a more measured view in response to business trends. However, the competitive landscape has shifted with the FDA approval of Eli Lilly’s Foundayo oral obesity drug in early April, posing fresh challenges for Novo Nordisk’s established market position.

Persistent overbought signals amid bullish momentum and rangebound trading

On the technical chart, NVO is currently trading above the SMA-20 at $41.27 and SMA-50 at $38.98, but remains below the SMA-200 at $49.67. The Ichimoku Kijun level at $41.47 acts as immediate support beneath the price. Daily momentum is positive, as the MACD has produced a buy signal and the Awesome Oscillator remains supportive, while the ADX shows a neutral trend, signaling low conviction. Multiple oscillators, including RSI at 73.37, Stoch RSI at 100, CCI at 164.64, and Bull/Bear Power (BBP) at 4.22, all indicate overbought conditions. Today the price has held within a narrow range of $45.75–$47.08, pointing to low intraday volatility and consolidation after early gains. Notably, there is a stark divergence, with ongoing upward momentum countered by persistent overbought signals across several indicators.

Consolidation favored as limited upside meets overbought conditions

In the near term, NVO is expected to trade within a weekly volatility band of $44.90–$47.10, reflecting typical price fluctuations around current levels. With the probability of further price increases estimated below 20%, consolidation or a modest decline appears more likely based on current daily and weekly technical signals. If the price breaks above $47.10, a bullish scenario may unfold, while a fall below $44.90 could trigger additional profit-taking and short-term weakness given the overbought backdrop.

Anton Kharitonov, expert at Traders Union, notes that Novo Nordisk's recent earnings beat was driven by strong product demand but arrives amid tightening guidance and fresh competition from Eli Lilly. He sees technical charts reflecting overbought signals with limited upside momentum and low probability of breakout above $47.10 in the near term. The analyst believes that consolidation is the base case unless support at $44.90 is breached. "Until Novo Nordisk clears $47.10 with conviction, I remain cautious and prefer to wait for clearer technical signals."

Earlier, analysts noted that Novo Nordisk’s strong financial performance was accompanied by persistent overbought technical signals and the risk of a short-term pullback. The current setup strengthens this view, as ongoing overbought conditions and fresh competitive headwinds point to increased downside risk if the price fails to hold above the $44.90 support level in the coming sessions.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.